Portfolio news

We’re excited to welcome Hemastatx to our portfolio. Hemastatx, a spin-off from KU Leuven, has emerged from stealth with funding from BaseLaunch, Gemma Frisius Fund and…

Basel, Switzerland – May 5, 2025 – metaLead Therapeutics AG (metaLead), a pioneering biotech company developing next-generation metal-binding therapies, announced today that it has secured…

Ilonov is harnessing groundbreaking discoveries to revolutionize treatment for metabolic disorders. By harvesting novel targets discovered from breakthrough research on the human muscle secretome, the…

Basel, Switzerland – 10 Feb, 2025, Phialogics AG has announced the appointment of Dr. Natalia Novac as Chief Executive Officer. Natalia has a great experience…

Gibela Therapeutics, a spin-off from the Cooperative Research Center in Biosciences (CIC bioGUNE), is pioneering RNA-based therapeutics for the treatment of liver diseases. The company,…

Basel, Switzerland – 9 Jan, 2025, Alentis Therapeutics, a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced positive topline…

Basel, Switzerland – 18 Dec, 2024, Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Richard Sachse, M.D., Ph.D., as Chief Medical Officer…

We are pleased to share that Stromal Therapeutics have published groundbreaking research in Cell, shedding light on a critical interplay between fibroblasts and the local…

Basel, Switzerland and Cambridge, MA – 9 Dec, 2024, Cimeio Therapeutics announced that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa…

MetaLead Therapeutics AG, a spin-out from the University of Zurich, is pioneering the field of metal-related diseases by focusing on novel therapeutic approaches for conditions…